Primary Category:
Radiation Oncology, Treatment Protocols
Disease Category:
Anal, Gastrointestinal
Status:
Closed
A Randomized Phase II Study of Nivolumab After Combined Modality Therapy (CMT) in High Risk Anal Cancer
Study has reached its accrual goal and is closed to accrual effective August 31, 2021.
NCT#03233711
Eligible for screening study DCP 001
